It is estimated that the human genome encodes 15% of proteins that are considered to be
disease-modifying. Only 2% of these proteins possess a druggable site that the approved …

Messenger RNA (mRNA) holds great potential in developing immunotherapy, protein
replacement, and genome editing. In general, mRNA does not have the risk of being …

Micelleplexes show great promise as effective polymeric delivery systems for nucleic acids.
Although studies have shown that spherical micelleplexes can exhibit superior cellular …

RNA-based therapeutics have emerged as promising approaches to modulate gene
expression and generate therapeutic proteins or antigens capable of inducing immune …

Recent advances in the manufacturing, modification, purification, and cellular delivery of
ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a …

Commensal and pathogenic bacteria continuously evolve to survive in diverse ecological
niches by efficiently coordinating gene expression levels in their ever-changing …

RNA therapeutics have undergone remarkable evolution since their inception in the late
1970s, revolutionizing medicine by offering new possibilities for treating previously …

Numerous genetic and epidemiologic studies have demonstrated an association between
elevated levels of lipoprotein (a)(Lp [a]) and cardiovascular disease. As a result, lowering Lp …

As nucleic acid (NA) technologies continue to revolutionize medicine, new delivery vehicles
are needed to effectively transport NA cargoes into cells. Uniform and length-tunable …

Inborn errors of metabolism (IEM) encompass a group of monogenic diseases affecting both
pediatric and adult populations and currently lack effective treatments. Some IEM such as …